Sun Pharmaceutical (SUNPHARMA) — Financial Results

Sun Pharmaceutical reported consolidated sales of ₹52,041.2 crores for FY25, up 69.9% YoY, with Q4 sales at ₹12,815.6 crores. Adjusted net profit reached ₹2,889 crores in Q4, a 32% YoY increase, while reported net profit was ₹2,149.9 crores. EBITDA margin stood at 29% for FY25. The company proposed a final dividend of ₹5.5 per share, adding to an interim dividend of ₹10.5, totaling ₹16 per share for FY25. A $100 million investment is planned for FY26 specialty product launches, primarily targeting promotions and sales force expansion without TV advertising. Tax rate rose to 19.8% in Q4 due to exhaustion of past losses.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUNPHARMA ✨ Ask AI About This

About Sun Pharmaceutical Industries Limited (SUNPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹4,50,643.09 Cr P/E: 41.3 ROE: 15.1% ROCE: 20.3%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

💡 Ask AI about this filing

"How does this financial results affect Sun Pharmaceutical Industries Limited's outlook?" "What did Sun Pharmaceutical Industries Limited announce on 29 May 2025?" "Is this positive or negative for SUNPHARMA?"

Ask AI Free →

📊 More SUNPHARMA filings

See all SUNPHARMA filings →

🔥 Also filed on 29 May 2025

APOLLOHOSP Apollo Hospitals Enterprise Limited Insider Trading APOLLOHOSP Apollo Hospitals Enterprise Limited Insider Trading SHRIRAMFIN Shriram Finance Limited Corporate Action VEDL Vedanta Limited Corporate Action WIPRO Wipro Limited Corporate Action BAJAJ-AUTO Bajaj Auto Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.